RAPP Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.0M.
Where they traded
Last open-market purchase: September 12, 2025 — 1.0 years ago, by PAUL STEVEN M .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 8,210 | $45.61 | $374.5K | 460,046 −1.8% of holding | |
| Yeleswaram Krishnaswamy 2 fills | Chief Development Officer | Sell 10b5-1 | 37,000 | $50.64 | $1.9M | 212,063 −14.9% of holding | |
| Ceesay Abraham | Chief Executive Officer | Sell 10b5-1 | 18,921 | $49.57 | $938.0K | 467,187 −3.9% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 13,160 | $50.00 | $658.0K | 232,862 −5.3% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 404 | $49.90 | $20.2K | 246,022 −0.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.